Evidence map›Paper›PMID 28899477›Full record

ReviewZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2017

[Research advances in pharmacogenomics of mercaptopurine].

Xiao-Xiao Chen, Shu-Hong Shen

Open access · greenAbstract readReview
In one paragraph

Review in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xiao-Xiao ChenDepartment of Hematology and Oncology, Shanghai Children's Medical Center, Medical School of Shanghai Jiaotong University, Shanghai 200127, China. cxxsunny9@aliyun.com.
Shu-Hong Shen
Shanghai Children's Medical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mercaptopurine is a common chemotherapeutic drug and immunosuppressive agent and plays an important role in the treatment of acute lymphoblastic leukemia and inflammatory bowel disease. It may cause severe adverse effects such as myelosuppression, which may result in the interruption of treatment or complications including infection or even threaten patients' lives. However, the adverse effects of mercaptopurine show significant racial and individual differences, which reveal the important role of genetic diversity. Recent research advances in pharmacogenomics have gradually revealed the genetic nature of such differences. This article reviews the recent research advances in the pharmacogenomics and individualized application of mercaptopurine.

Indexed as

Antimetabolites, AntineoplasticHumansInosine TriphosphataseMercaptopurineMethyltransferasesNudix HydrolasesPharmacogeneticsPolymorphism, GeneticPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrophosphatasesAntimetabolites, AntineoplasticInosine TriphosphataseITPA protein, humanMercaptopurineMethyltransferasesNudix HydrolasesNUDT15 protein, humanPyrophosphatasesthiopurine methyltransferase

Identifiers

PMID28899477
PMCPMC7403070
OpenAlexW2989961211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.